Nicaragua vs Rwanda: Death rate from cancer
Nicaragua
39.65 deaths per 100,000 people
in 2021
Rwanda
40.36 deaths per 100,000 people
in 2021
Nicaragua rank
179th
Rwanda rank
176th
Death rate from cancer over time
- Nicaragua
- Rwanda
How they compare
Rwanda currently reports 40.36 deaths per 100,000 people against 39.65 deaths per 100,000 people in Nicaragua, a difference of 0.71 deaths per 100,000 people.
Across all 22 years both countries report, Rwanda has been ahead every year.
Nicaragua ranks 179th and Rwanda ranks 176th of 194 countries.
Rwanda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Nicaragua | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 38.37 deaths per 100,000 people | 54.61 deaths per 100,000 people | 16.24 deaths per 100,000 people | Rwanda |
| 2010s | 41.79 deaths per 100,000 people | 49.52 deaths per 100,000 people | 7.73 deaths per 100,000 people | Rwanda |
| 2020s | 41.11 deaths per 100,000 people | 44.03 deaths per 100,000 people | 2.92 deaths per 100,000 people | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Nicaragua or Rwanda?
- Rwanda, at 40.36 deaths per 100,000 people against 39.65 deaths per 100,000 people in Nicaragua as of 2021.
- What is the difference in death rate from cancer between Nicaragua and Rwanda?
- 0.71 deaths per 100,000 people, with Rwanda ahead.
- How many years of comparable data are there for Nicaragua and Rwanda?
- 22 years are reported by both, from 2000 to 2021.
- How do Nicaragua and Rwanda rank globally for death rate from cancer?
- Nicaragua ranks 179th and Rwanda ranks 176th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.